Related Experiment Videos
Polyclonal versus monoclonal rejection prophylaxis after heart transplantation: a randomised study
A H Balk1, K Meeter, M L Simoons
1Thoraxcenter and Department of Internal Medicine I, University Hospital Rotterdam Dijkzigt, Rotterdam, The Netherlands.
Summary
Monoclonal OKT3 and polyclonal antilymphocyte globulins (ALG) induction therapies show similar effectiveness in preventing heart transplant rejection. OKT3 is preferred due to fewer side effects, though shorter ALG courses are also effective.
Area of Science:
- Immunology
- Transplantation Medicine
- Clinical Research
Background:
- Induction therapy is crucial in heart transplantation to prevent acute rejection.
- Polyclonal antilymphocyte globulins (ALG) and monoclonal T-cell-specific antibodies are commonly used, but their comparative efficacy and safety profiles remain debated.
- Optimizing induction protocols can improve patient outcomes and reduce treatment-related complications.
Purpose of the Study:
- To compare the efficacy and safety of a 7-day course of polyclonal ALG versus monoclonal OKT3 as induction therapy in heart transplant recipients.
- To evaluate the impact of these induction strategies on rejection rates, infection incidence, and long-term patient survival.
- To determine the optimal choice of induction agent based on clinical outcomes and adverse events.
Main Methods:
- A prospective study involving 55 heart transplant recipients randomized to receive either polyclonal ALG (n=28) or monoclonal OKT3 (n=27) for 7 days.
- All patients received concomitant azathioprine and low-dose steroids.
- Key outcome measures included freedom from rejection, infection incidence, and 1- and 2-year patient survival rates.
Main Results:
- No significant differences were observed between the OKT3 and ALG groups regarding freedom from rejection or infection incidence.
- Patient survival rates at 1 and 2 years post-transplant were high and comparable in both groups (96%).
- The ALG course required discontinuation in 20 patients due to severe flares, whereas OKT3 was associated with no severe side effects.
Conclusions:
- Both polyclonal ALG and monoclonal OKT3 are equally effective for rejection prophylaxis in heart transplant recipients.
- Monoclonal OKT3 may be preferred due to its superior safety profile and lack of severe adverse events.
- Shorter courses of ALG may offer comparable efficacy, presenting a potential alternative, but require careful monitoring for side effects.